Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (NYSE: VEEV) has entered a strategic partnership with Impel NeuroPharma to support the commercialization of Impel’s migraine treatment INP104, branded TRUDHESA™, pending FDA approval. The collaboration will enhance Impel's pre-launch efforts through Veeva's Commercial Cloud, ensuring a robust strategy for physician engagement and patient data management. TRUDHESA™ utilizes Impel's Precision Olfactory Delivery technology for effective drug delivery, optimizing treatment for migraines. This agreement marks a significant step toward addressing high unmet needs in CNS therapeutics.
Veeva Systems (NYSE: VEEV) has announced that six out of the seven largest global CROs have joined its Veeva Vault CDMS partner program, enhancing clinical data management capabilities industry-wide. This program aims to modernize clinical trials and improve trial performance through advanced technology. CROs such as Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health will leverage Veeva's technology for faster and more efficient trials. The move supports the increasing need for speed and efficiency in clinical research.
Veeva Systems (NYSE: VEEV) announced that Epredia is implementing Veeva Vault Quality and Vault RIM applications to automate quality management and regulatory operations, enhancing efficiency in change control processes. This integration aims to improve collaboration, reduce manual overhead, and comply with diagnostic reporting regulations including 21 CFR part 820 and ISO13485. Notably, Epredia's adoption of Veeva's solutions is expected to streamline product lifecycle management and facilitate quicker market access for diagnostic products.
Veeva Systems (NYSE: VEEV) announced overwhelming shareholder support, with 99% approving its conversion to a public benefit corporation effective February 1, 2021. This makes Veeva the largest publicly traded company to adopt this model, which allows it to balance interests among stakeholders, including customers, employees, and shareholders. The change aligns with Veeva's mission to enhance productivity in the life sciences sector and create quality job opportunities. Additionally, a proposal to declassify its board received near unanimous approval.
Veeva Systems (NYSE: VEEV) announced that 99% of shareholders voted in favor of its proposal to become a public benefit corporation (PBC), effective Feb. 1, 2021. This conversion makes Veeva the largest publicly traded company to adopt such a status, maintaining its for-profit status while prioritizing the interests of multiple stakeholders. The decision aligns with Veeva's mission to enhance human health and ensures accountability to customers, employees, and shareholders. Additionally, shareholders approved a proposal to declassify the board of directors.
Veeva Systems (NYSE: VEEV) has partnered with Integra LifeSciences to implement Veeva Vault CDMS for their clinical trials. This solution enhances electronic data capture, coding, data cleaning, and reporting, leading to reduced database build times. Hugo Cervantes from Veeva highlighted the importance of flexibility and speed in MedTech trials, emphasizing how this partnership aims to innovate for better patient care. Veeva Vault CDMS is gaining traction across various sectors, making clinical research more efficient.
Veeva Systems (NYSE: VEEV) announced that Samsung Biologics has implemented Veeva Vault QMS to enhance its quality management processes. This integration complements Samsung's use of Veeva Vault QualityDocs, streamlining document control for improved visibility and compliance. With this upgrade, Samsung Biologics strengthens its quality processes across global operations, responding to evolving regulatory standards. James Choi, CIO of Samsung Biologics, emphasized the importance of unified quality management for effective manufacturing, highlighting the strategic partnership with Veeva to drive innovation.
Veeva Systems (NYSE: VEEV) announced that Simbec-Orion, a contract research organization, will implement the Veeva Vault CTMS and Veeva Vault eTMF to enhance clinical trial operations. This adoption aims to digitize workflows and improve real-time data sharing, boosting trial efficiency. Simbec-Orion's CIO noted that Veeva's solutions provide a digital foundation for effective clinical trials. The integration allows for better collaboration and compliance, ultimately accelerating trial execution while maintaining high-quality data for sponsors.
Veeva Systems (NYSE: VEEV) announced that GenesisCare Clinical CRO has integrated Veeva Vault eTMF, CTMS, and Payments into its operations to enhance trial processes globally. This partnership allows GenesisCare to utilize a secure cloud platform for streamlined drug development, enhancing efficiency in managing clinical studies. The integration aims to simplify data sharing, document management, and payment processes, contributing to quicker and more effective trial execution as GenesisCare expands its services.
Veeva Systems reported impressive growth in its fiscal third quarter ending October 31, 2020, with total revenues reaching $377.5 million, a 34% increase year-over-year. Subscription services revenues also rose 34% to $302.9 million. Operating income was $101.3 million, up 25%, while net income increased 18% to $97.0 million. The company provided guidance for Q4 revenues of $378-$380 million and fiscal year revenues of $1.446-$1.448 billion. Veeva emphasized ongoing digital transformation in life sciences as a driver of growth.